Patrick Juliebø-Jones1,2*
Ingunn Roth1
Lazaros Tzelves3Karin M. Hjelle1,2Christian Arvei Moen1,2
Francesco Esperto4
Bhaskar K. Somani5Christian Beisland1,2
- 1Department of Urology, Haukeland University Hospital, Bergen, Norway
- 2Department of Clinical Medicine, University of Bergen, Bergen, Norway
- 3Second Department of Urology, National and Kapodistrian University of Athens, Sismanogleio General Hospital, Athens, Greece
- 4Department of Urology, Campus Bio-Medico University, Rome, Italy
- 5Department of Urology, University Hospital Southampton, Southampton, United Kingdom
Male stress urinary incontinence is a debilitating condition, which can occur after prostate surgery. In persistent cases, surgery is indicated and a number of options are available. This includes one of the male slings, Adjustable transobturator male system (ATOMSTM, A.M.I, Austria). There are now an increasing number of studies published. This review provides an overview of the current status of this implant device including technical considerations, surgical outcomes and potential advantages and disadvantages compared to alternatives such as the artificial urinary sphincter.
Introduction
Male stress urinary incontinence (SUI) is one of the major long term adverse effects that can occur following prostate surgery and in particular, radical prostatectomy (RP). According to a recent analysis of the SEER (Surveillance, Epidemiology and End Results) database, 6% of patients who have undergone RP, will later go on to have incontinence surgery (1). Risk factors include larger prostate size, membranous urethral length and age (2, 3). The resulting impact on a patient´s quality of life can be considerable. As for many other patient groups who suffer UI, it can lead to embarrassment and deep restrictions upon a persońs activities of daily living (4). This sense of embarrassment can lead to delays in seeking formal treatment (5). Once the indications for incontinence surgery have been fulfilled, a range of potential surgeries are available. Local expertise, surgeon preference and availability impact the range of options a patient will be offered. Other elements to consider include the symptom severity, manual dexterity as well as previous radiotherapy (6). While use of bulking agents is the least invasive option, success rates are low and it is no longer recommended by the European Association of Urology guidelines (7). Rather, implantable devices form the mainstay of surgery for male SUI. This treatment can be broadly categorised into two groups: the artificial urinary sphincter (AUS) and male slings. The latter can be further divided into devices that are referred to as adjustable and those that are fixed. Regarding the former, several different such slings are available including ATOMSTM (A.M.I, Austria). First described in a cadaveric setting in 2005, it was developed and in use for clinical purposes since 2008 (8, 9). Since then, a gradual increase in original studies have been published reporting outcomes associated with the device including for patients with a broader selection criteria. It is usually compared against the AMS 800TM, which since it has been commercially available since 1983, is the intervention for which most evidence is available and as a result, it has long been the reference treatment (10). However, the advances recorded with use of ATOMSTM have generated debate in terms of the role it should play for male SUI post prostate surgery including when and if it can be a preferred choice over the AMS 800TM.
Our aim was to review the available literature and provide an update on its current status including technical considerations, surgical outcomes and the guideline perspectives.
Methods
A comprehensive but non-systematic search of the literature was performed to identify studies on ATOMSTM that were available over the past 15 years since it was first described. Only those published in the English language were considered. Bibliographic databases used included Medline and Google Scholar. The following key topics were identified: Technical considerations, Short term outcomes, Long term outcomes, Complication burden, Re-do surgery, Previous radiotherapy, ATOMs for severe male SUI, Advantages/disadvantages, Recommendations from international guidelines, Challenges and Future directions.
History and technical considerations
The initial clinical experiences to be published appeared a few years after its development. The Austrian study by Seweryn et al., which included 38 patients since 2009 was among the first (11). The authors reported continence success (defined as maximum one pad per 24 hours) at 60.5%. Since that report, the device has undergone modifications, most notably in 2013 with a silicone rather than titanium port cover and after 2014, this could be placed in the scrotum with the port pre-attached. This element along with its mesh arms and silicone cushion form key characteristics that distinguish it from adjustable male sling alternatives such as the Remeex system (Neomedic, Spain), consisting of a suprapubic pressure adjusting device (“varitensor”) connected via two traction threads to a suburethral prosthesis made of polypropylene and the Argus sling (Promedon, Argentina) (6, 12). The latter features a silicone cushion pad to compress the bulbar urethra, cone shaped columns on either side and “washers” to secure tension (13).
The switch to a silicone covered port was driven by early reports of device explantation as a result of reported titanium intolerance (14). The transition away from the inguinal port placement has reduced the total number of incisions required from two down to only one. The 3rd generation port is also smaller. In a multi-centre study from Germany and Spain, port related complications were 19.2% with the first device but 6.5% with the 3rd generation model (15).
In a recent series by Giammò et al., the mean operative time was 51 min, and most studies report similar results that total operative times under 60 min (16). Hospital discharge is usually planned for within 24 h and adjustments can be made to the port in the outpatient setting. In a recent systematic review, the mean number of fillings required was 2.4 (17).
Symptom improvement
In a 2019 meta-analysis of pooled data from 1,393 patients (20 studies), 90% were found to have symptom improvement at follow up (18). Sample sizes of the included studies ranged from 13 to 287 patients. Seven of the included studies reported patient satisfaction and rates ranged from 61.8% to 100%. Interestingly, in the study with a satisfaction rate of 61.8%, 39% of the sample had undergone previous radiotherapy and the explantation rate was 31.5% (19). In contrast, in the study recording 100% satisfaction, only 7.7% had received previous radiotherapy and the explantation rate was zero (20). More research is needed to determine what affects long term patient satisfaction.
Pooling data on dryness rates is difficult given the varying definitions for this parameter. In a retrospective study of 155 patients by Angulo et al. published in 2020, which had a mean follow up of 60 months, 72.1% achieved a dry status as defined by no pads or one security pad (21). Friedl et al. reported on the impact of ATOMSTM on sexual function (22). Erectile function scores were improved at six months follow up and 38% of the sample started to have intercourse again after having stopped previously. Dual implantation of penile prosthesis and ATOMSTM has been reported. To date, only data on simultaneous AUS placement at the time of surgical repair of refractory bladder neck contracture has been reported (23–25).
Complications
Muhlstadt et al. reported the overall complication rate to be 27.3% in their series of 187 patients. The authors found previous radiotherapy as well as previous urethral surgery to be significant predictors of a post operative complication (15). The learning curve associated with ATOMS was also studied and found the rate of complication to fall from 44% to 21.1% after 25 cases were performed. Angulo et al. reported an explantation rate of 8.5% in their multi-centre study of 902 patients (26). The two commonest indications for removal were persistent incontinence and port erosion. Explantation rates do vary, with reports of as high as 19% previously recorded (27). Possible reasons for such wide variations include different follow up lengths and the proportion of patients with radiotherapy. Giammo et al. reported the survival of the ATOMSTM device to be 97% at 12 months and 89.9% at 60 months (28). As with all prosthetic devices, infection can be a major complication and rates between 2.7%–6.2% have been reported (8). Predictive nomograms have become increasingly popular across many areas of urology and tools are now available in the setting of ATOMSTM (29, 30). This includes the tool developed by Dorado et al., which serves to predict risk of failure (30). Variables included in that tool are Male Stress Incontinence Grading Scale (MSIGS), 24-h pad test and history of radiotherapy.
Guidelines perspective
While ATOMSTM surgery is covered in the latest EAU guideline, no formal recommendations regarding any of the adjustable male slings are given as the panel determined the current body of literature to be still lacking (31). Fixed male slings do however receive a recommendation. Here it is stressed that the role of such fixed devices should be limited to the setting of men with mild to moderate incontinence. Again however, it is underscored that the evidence is also limited for this intervention type. The American Urological Association guidelines do not make any specific comment regarding the ATOMSTM device (2). Male slings as a group are discussed with a similar recommendation that they are avoided in the setting of severe incontinence. These positions shared by the EAU and AUA guidelines are very similar to those from the Urological Society of India, Canadian Urological Association (CUA) and the International Consultation on Incontinence (ICI) (32–34). Of note, some of these guidelines are not updated yearly. The CUA document was disseminated in 2012, which was before the last generation of ATOMSTM was released and there have been multiple original studies published since then (32). Bhatt et al. evaluated all five of these guidelines on the topic of post prostatectomy incontinence using the Appraisal of Guidelines for Resarch and Evaluation II (AGREE II) tool on domains such as scope, clarity and applicability (35). The authors concluded the AUA guidelines to score highest.
Advantages and disadvantages compared to AUS
There are several advantages that can be found with the ATOMSTM device. Firstly, and in contrast to fixed slings such as the AdVance™ and the AUS, adjustments can be made without the need to return to surgery and the scrotal port placement allows for ease of access when doing so. Also, if there is a complication that is localised to the port only, the port can be removed in isolation. While this means that further adjustments cannot be made, it avoids the complete explantation of the device. ATOMSTM is also associated with a shorter operative time compared to AUS. In a propensity-score-matched analysis comparing the two devices, the mean operative time associated with ATOMSTM was significantly shorter (56 vs. 100 min, p < 0.001) (36). In contrast to AUS where satisfactory manual dexterity and cognition is required, patients are not required to manipulate the ATOMSTM device themselves. While simpler methods for activation of the AMS 800 have been proposed, these are not yet in clinical use. Even if patients have normal cognition and dexterity at the time of surgery, if they later suffer an acute medical event such as a stroke that impairs their upper motor function and/or their cognitive status, this can pose obvious problems for those with an AUS in situ. From a practical perspective, patients with AUS also require greater caution when performing a subsequent cystoscopy as well as the need for a urologist to attend the operating theatre to deactivate the AUS device if undergoing surgery by another specialty when catheterization is being performed. From an anatomical perspective, the non-circumferential design reduces the risk of urethral atrophy and erosion. Infection rates are also lower when compared to AUS as well as Argus and Remeex. There is a potential cost advantage too, with Constable et al. reporting costs associated with ATOMSTM procedure to be £6,000 compared to £9,000 with the AUS (37).
However, as raised by international guidelines, the levels of evidence supporting the role of ATOMSTM is more limited compared to AUS. This is perhaps the biggest disadvantage. How these abovementioned advantages translate overall is thus yet to be fully determined.
While the body of original studies for ATOMSTM does exceed 20, many are single centre and retrospective in nature and to date, there have been no randomised studies, which have placed ATOMSTM head-to-head against AUS. The MASTER trial did compare male slings with AUS but most of the slings included in that non inferiority trial were the fixed type and a full breakdown is not given (38). The authors found no differences in SUI burdens at follow up. However, secondary outcomes such as complication rates did favour AUS. The proposed advantages of the AUS are its feasibility in patients with previous radiotherapy and those with severe SUI.
Challenges
Beyond the abovementioned lack of studies in comparison to other incontinence devices, other challenges exist. For example, the lack of standardised reporting as well as lack of consensus regarding reporting of SUI. Some author groups prefer to use pad count while others choose pad weight. Furthermore, for each one of these, consensus is lacking regarding how to how to grade severity. This makes comparisons between studies more difficult. Another area that appears to lack standardisation is reporting of port removal/total explantation. For example, some groups report this as a complication but others consider it a late treatment failure. Unless a reader studies the results very carefully and is aware of this, one can easily misinterpret the complication burdens across different studies.
Heterogeneity in other forms is also common among studies. For example, populations with both RP and benign prostate surgery patients and some having had radiotherapy. Furthermore, radiotherapy type (e.g., adjuvant vs. salvage) is not routinely specified in these studies. Studies reporting their experiences with ATOMSTM over several years will usually include patients have had different generations of ATOMSTM devices. This can introduce further bias.
Conclusions
With over a decade of published results associated with ATOMSTM now available, this adjustable sling device has positioned itself as an effective surgical option. It offers strengths that can complement the longer established AUS. Further studies will allow for optimal selection criteria to be further defined and its recommended role in international guidelines to be delineated. This includes the role of ATOMSTM in the setting of previous radiation as well as severe incontinence.
Author contributions
PJ-J: Conceptualization, Data curation, Formal Analysis, Investigation, Writing – original draft, Writing – review & editing. IR: Writing – original draft, Writing – review & editing. LT: Conceptualization, Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing. KH: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. CM: Conceptualization, Methodology, Writing – original draft, Writing – review & editing. FE: Methodology, Writing – original draft, Writing – review & editing. BS: Supervision, Writing – original draft, Writing – review & editing. CB: Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Kim PH, Pinheiro LC, Atoria CL, Eastham JA, Sandhu JS, Elkin EB. Trends in the use of incontinence procedures after radical prostatectomy: a population based analysis. J Urol. (2013) 189(2):602–8. doi: 10.1016/j.juro.2012.08.246
2. Sandhu JS, Breyer B, Comiter C, Eastham JA, Gomez C, Kirages DJ, et al. Incontinence after prostate treatment: AUA/SUFU guideline. J Urol. (2019) 202(2):369–78. doi: 10.1097/JU.0000000000000314
3. Katsimperis S, Juliebø-Jones P, Ta A, Tandogdu Z, Al-Bermani O, Bellos T, et al. Surgical techniques to preserve continence after robot-assisted radical prostatectomy. Front Surg. (2023) 10:1289765. doi: 10.3389/fsurg.2023.1289765
4. Juliebo-Jones P, Coulthard E, Mallam E, Archer H, Drake MJ. Understanding the impact of urinary incontinence in persons with dementia: development of an interdisciplinary service model. Adv Urol. (2021) 2021:9988056. doi: 10.1155/2021/9988056
5. Braun AE, Washington SL, Cowan JE, Hampson LA, Carroll PR. Impact of stress urinary incontinence after radical prostatectomy on time to intervention, quality of life and work status. Urology. (2023) 180:242–8. doi: 10.1016/j.urology.2023.06.027
6. Anding R, Comiter C, Tse V, Hübner W. Current surgical management of postprostatectomy incontinence—workup, options and decision making. Continence. (2023) 8:101044. doi: 10.1016/j.cont.2023.101044
7. Gacci M, Sakalis VI, Karavitakis M, Cornu J-N, Gratzke C, Herrmann TR, et al. European association of urology guidelines on male urinary incontinence. Eur Urol. (2022) 82(4):387–98. doi: 10.1016/j.eururo.2022.05.012
8. Tellez C, Szczesniewski J, Virseda-Chamorro M, Arance I, Angulo JC. Update on adjustable trans-obturator male system (ATOMS) for male incontinence after prostate cancer surgery. Curr Oncol. (2023) 30(4):4153–65. doi: 10.3390/curroncol30040316
9. Bauer W, Karik M, Schramek P. The self-anchoring transobturator male sling to treat stress urinary incontinence in men: a new sling, a surgical approach and anatomical findings in a cadaveric study. BJU Int. (2005) 95(9):1364–6. doi: 10.1111/j.1464-410X.2005.05530.x
10. James MH, McCammon KA. Artificial urinary sphincter for post-prostatectomy incontinence: a review. Int J Urol. (2014) 21(6):536–43. doi: 10.1111/iju.12392
11. Seweryn J, Bauer W, Ponholzer A, Schramek P. Initial experience and results with a new adjustable transobturator male system for the treatment of stress urinary incontinence. J Urol. (2012) 187(3):956–61. doi: 10.1016/j.juro.2011.10.138
12. Kim WB, Lee SW, Lee KW, Kim JM, Kim YH, Kim ME. Readjustable midurethral sling (REMEEX system) in obese women. Investig Clin Urol. (2019) 60(6):488–95. doi: 10.4111/icu.2019.60.6.488
13. Romano SV, Metrebian SE, Vaz F, Muller V, D'Ancona CA, Costa DESEA, et al. An adjustable male sling for treating urinary incontinence after prostatectomy: a phase III multicentre trial. BJU Int. (2006) 97(3):533–9. doi: 10.1111/j.1464-410X.2006.06002.x
14. Ko KJ, Kim SJ, Cho ST. Sling surgery for male urinary incontinence including post prostatectomy incontinence: a challenge to the urologist. Int Neurourol J. (2019) 23(3):185–94. doi: 10.5213/inj.1938108.054
15. Mühlstädt S, Angulo JC, Mohammed N, Schumann A, Fornara P. Complications of the urinary incontinence system ATOMS: description of risk factors and how to prevent these pitfalls. World J Urol. (2020) 38:1795–803. doi: 10.1007/s00345-019-02962-w
16. Giammo A, Ammirati E, Tullio A, Bodo G, Manassero A, Gontero P, et al. Implant of ATOMS(R) system for the treatment of postoperative male stress urinary incontinence: results of a single centre. Int Braz J Urol. (2019) 45(1):127–36. doi: 10.1590/s1677-5538.ibju.2018.0171
17. Angulo JC, Schonburg S, Giammo A, Abellan FJ, Arance I, Lora D. Systematic review and meta-analysis comparing adjustable transobturator male system (ATOMS) and adjustable continence therapy (ProACT) for male stress incontinence. PLoS One. (2019) 14(12):e0225762. doi: 10.1371/journal.pone.0225762
18. Esquinas C, Angulo JC. Effectiveness of adjustable transobturator male system (ATOMS) to treat male stress incontinence: a systematic review and meta-analysis. Adv Ther. (2019) 36(2):426–41. doi: 10.1007/s12325-018-0852-4
19. Krause J, Tietze S, Behrendt W, Nast J, Hamza A. Reconstructive surgery for male stress urinary incontinence: experiences using the ATOMS[(R)] system at a single center. GMS Interdiscip Plast Reconstr Surg DGPW. (2014) 3:Doc15. doi: 10.3205/iprs000056
20. Gonzalez SP, Cansino JR, Portilla MA, Rodriguez SC, Hidalgo L, De la Pena J. First experience with the ATOMS((R)) implant, a new treatment option for male urinary incontinence. Cent European J Urol. (2014) 67(4):387–91. doi: 10.5173/ceju.2014.04.art14
21. Angulo JC, Virseda-Chamorro M, Arance I, Ruiz S, Ojea A, Carballo M, et al. Long-term outcome of adjustable transobturator male system for stress urinary incontinence in the Iberian multicentre study. Neurourol Urodyn. (2020) 39(6):1737–45. doi: 10.1002/nau.24410
22. Friedl A, Bauer W, Rom M, Kivaranovic D, Luftenegger W, Brossner C. Sexuality and erectile function after implantation of an adjustable transobturator male system (ATOMS) for urinary stress incontinence. A multi-institutional prospective study. Arch Ital Urol Androl. (2016) 87(4):306–11. doi: 10.4081/aiua.2015.4.306
23. Krughoff K, Peterson AC. Bladder neck contractures stabilize after placement of the artificial urinary sphincter. J Urol. (2023) 209(5):981–91. doi: 10.1097/JU.0000000000003194
24. Uguzova S, Beisland C, Honore A, Juliebo-Jones P. Refractory bladder neck contracture (BNC) after radical prostatectomy: prevalence, impact and management challenges. Res Rep Urol. (2023) 15:495–507. doi: 10.2147/RRU.S350777
25. Falcone M, Preto M, Ammirati E, Blecher G, Carone R, Gontero P, et al. Dual implantation of penile prosthesis and ATOMS((R)) system for post-prostatectomy erectile dysfunction and urinary incontinence: a feasibility study. Int J Impot Res. (2021) 33(6):577–82. doi: 10.1038/s41443-020-0320-y
26. Angulo JC, Schonburg S, Giammo A, Queissert F, Gonsior A, Gonzalez-Enguita C, et al. Artificial urinary sphincter or a second adjustable transobturator male system offer equivalent outcomes in patients whom required revision on the initial ATOMS device: an international multi-institutional experience. Neurourol Urodyn. (2021) 40(3):897–909. doi: 10.1002/nau.24646
27. Caremel R, Corcos J. Incontinence after radical prostatectomy: anything new in its management? Can Urol Assoc J. (2014) 8(5-6):202–12. doi: 10.5489/cuaj.1349
28. Giammo A, Ammirati E. Long-term survival rate of ATOMS implant for male stress urinary incontinence and management of late complications. J Clin Med. (2023) 12(6):2296. doi: 10.3390/jcm12062296
29. Jones P, Pietropaolo A, Chew BH, Somani BK. Atlas of scoring systems, grading tools, and nomograms in endourology: a comprehensive overview from the TOWER endourological society research group. J Endourol. (2021) 35(12):1863–82. doi: 10.1089/end.2021.0124
30. Dorado JF, Angulo JC. Refined nomogram incorporating standing cough test improves prediction of adjustable trans-obturator male system (ATOMS) success to treat post-prostatectomy male stress incontinence. J Pers Med. (2022) 12(1):94. doi: 10.3390/jpm12010094
31. Gravas S, Cornu J, Gacci M, Gratzke C, Herrmann T, Mamoulakis C, et al. EAU Guidelines on Management of Non-neurogenic Male LUTS Including Benign Prostatic Obstruction. Arnhem, the Netherland, European Association of Urology. 2022.
32. Bettez M, Tule M, Carlson K, Corcos J, Gajewski J, Jolivet M, et al. 2012 update: guidelines for adult urinary incontinence collaborative consensus document for the Canadian urological association. Can Urol Assoc J. (2012) 6(5):354–63. doi: 10.5489/cuaj.12248
33. Sinha S, Agarwal MM, Vasudeva P, Khattar N, Madduri VKS, Yande S, et al. The urological society of India guidelines for the evaluation and management of nonneurogenic urinary incontinence in adults (executive summary). Indian J Urol. (2019) 35(3):185. doi: 10.4103/iju.IJU_125_19
34. Averbeck MA, Woodhouse C, Comiter C, Bruschini H, Hanus T, Herschorn S, et al. Surgical treatment of post-prostatectomy stress urinary incontinence in adult men: report from the 6th international consultation on incontinence. Neurourol Urodyn. (2019) 38(1):398–406. doi: 10.1002/nau.23845
35. Bhatt NR, Pavithran A, Ilie C, Smith L, Doherty R. Post-prostatectomy incontinence: a guideline of guidelines. BJU Int. (2023). doi: 10.1111/bju.16233. [Epub ahead of print].
36. Geretto P, Ammirati E, Falcone M, Manassero A, Agnello M, Della Corte M, et al. Comparison study between artificial urinary sphincter and adjustable male sling: a propensity-score-matched analysis. J Clin Med. (2023) 12(17):5489. doi: 10.3390/jcm12175489
37. Constable L, Cotterill N, Cooper D, Glazener C, Drake MJ, Forrest M, et al. Male synthetic sling versus artificial urinary sphincter trial for men with urodynamic stress incontinence after prostate surgery (MASTER): study protocol for a randomised controlled trial. Trials. (2018) 19(1):131. doi: 10.1186/s13063-018-2501-2
Keywords: adjustable transobturator male system, artificial urinary sphincter, male stress urinary incontinence, post prostatectomy incontinence, ATOMS system
Citation: Juliebø-Jones P, Roth I, Tzelves L, Hjelle KM, Moen CA, Esperto F, Somani BK and Beisland C (2024) Current status of the adjustable transobturator male system (ATOMSTM) for male stress urinary incontinence. Front. Surg. 11:1377788. doi: 10.3389/fsurg.2024.1377788
Received: 28 January 2024; Accepted: 6 March 2024;
Published: 19 March 2024.
Edited by:
Vito Mancini, University of Foggia, ItalyReviewed by:
Francesco Sessa, Careggi University Hospital, Italy© 2024 Juliebø-Jones, Roth, Tzelves, Hjelle, Moen, Esperto, Somani and Beisland. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Patrick Juliebø-Jones jonesurology@gmail.com